<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05029882</url>
  </required_header>
  <id_info>
    <org_study_id>M21-404</org_study_id>
    <secondary_id>2021-002258-98</secondary_id>
    <nct_id>NCT05029882</nct_id>
  </id_info>
  <brief_title>Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer Receiving Intravenous (IV) ABBV-400</brief_title>
  <official_title>A Phase 1 First in Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-400 in Adult Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and is associated&#xD;
      with poor prognosis and limited treatment options. The purpose of this study is to assess&#xD;
      adverse events and change in disease activity when ABBV-400 is given to adult participants to&#xD;
      treat advanced solid tumors.&#xD;
&#xD;
      ABBV-400 is an investigational drug being developed for the treatment of NSCLC. Study doctors&#xD;
      put the participants in groups called treatment arms. The Recommended Phase 2 dose (RP2D)&#xD;
      will be explored. Each treatment arm receives a different dose of ABBV-400. This study will&#xD;
      include a dose escalation phase to determine the best dose of ABBV-400, followed by a dose&#xD;
      expansion phase to confirm the dose. Approximately 100 adult participants with NSCLC, or&#xD;
      advanced solid tumors, will be enrolled in the study in approximately 7-10 sites in the Dose&#xD;
      Escalation phase and 80-85 sites in the Dose Expansion phase worldwide.&#xD;
&#xD;
      In the Dose Escalation arms, participants will receive intravenous (IV) escalating doses of&#xD;
      ABBV-400 monotherapy. In the Dose Expansion arms, participants with wtEGFR NSCLC or with&#xD;
      mutEGFR NSCLC will receive intravenous (IV) ABBV-400 monotherapy.&#xD;
&#xD;
      There may be higher treatment burden for participants in this trial compared to their&#xD;
      standard of care. Participants will attend regular visits during the study at an approved&#xD;
      institution (hospital or clinic). The effect of the treatment will be frequently checked by&#xD;
      medical assessments, blood tests, questionnaires and side effects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 13, 2021</start_date>
  <completion_date type="Anticipated">June 28, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 28, 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change it to Objective Response Rate (ORR)</measure>
    <time_frame>Up to Month 24</time_frame>
    <description>ORR defined as percentage of participants with confirmed best overall response of Confirmed complete response (CR) and partial response (PR) per investigator review according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) for Participants with Confirmed CR/PR per RECIST v1.1</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>DOR is defined for participants achieving a confirmed CR+PR as the time from the initial response of CR+PR per investigator review according to RECIST 1.1 criteria to disease progression or death of any cause, whichever occurs earlier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS per RECIST v1.1</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>Progression-free survival (PFS) is defined as time from first study treatment to a documented disease progression according to RECIST version 1.1, as determined by the investigator, or death due to any cause, whichever occurs earlier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>Overall survival (OS) is defined as time from first study treatment to death due to any cause.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Part 1 (Monotherapy Dose Escalation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with advanced solid tumors will receive escalating doses of ABBV-400.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2a (wtEGFR NSCLC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with c-Met overexpressing advanced non-squamous wtEGFR NSCLC will receive ABBV-400 at the Recommended Phase 2 dose (RP2D).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2b (mutEGFR NSCLC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with non-squamous mutEGFR NSCLC will receive ABBV-400 at the RP2D.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABBV-400</intervention_name>
    <description>Intravenous (IV) Infusion</description>
    <arm_group_label>Part 1 (Monotherapy Dose Escalation)</arm_group_label>
    <arm_group_label>Part 2a (wtEGFR NSCLC)</arm_group_label>
    <arm_group_label>Part 2b (mutEGFR NSCLC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologic malignant solid tumor diagnosis (World Health Organization [WHO] criteria).&#xD;
&#xD;
          -  Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.&#xD;
&#xD;
          -  For Part 1 only - history of advanced solid tumor that has progressed on all standard&#xD;
             of care therapy and are not amenable to surgical resection or other approved&#xD;
             therapeutic options that have demonstrated clinical benefit.&#xD;
&#xD;
          -  For Part 2 only - history of advanced non-squamous wtEGFR or mutEGFR Non-Small Cell&#xD;
             Lung Cancer (NSCLC) and are c-Met positive that has progressed after treatment per the&#xD;
             protocol.&#xD;
&#xD;
          -  Should have no more than 2 lines of prior cytotoxic chemotherapy excluding adjuvant&#xD;
             therapy and must have advanced NSCLC that is not amenable to surgical resection or&#xD;
             other approved therapeutic options that have demonstrated clinical benefit.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.&#xD;
&#xD;
          -  Laboratory values meeting the criteria outlined in the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of interstitial lung disease (ILD) or pneumonitis that required treatment with&#xD;
             systemic steroids, nor any evidence of active ILD or pneumonitis.&#xD;
&#xD;
          -  History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis&#xD;
             obliterans), drug-induced pneumonitis, or idiopathic pneumonitis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ABBVIE INC.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>844-663-3742</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Univ of Colorado Cancer Center /ID# 231574</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Carolina BioOncology Institute /ID# 231541</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists - Fairfax /ID# 231575</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East /ID# 232008</name>
      <address>
        <city>Kashiwa-shi</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital /ID# 232007</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pan American Center for Oncology Trials, LLC /ID# 231580</name>
      <address>
        <city>Rio Piedras</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 30, 2021</study_first_submitted>
  <study_first_submitted_qc>August 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <keyword>ABBV-400</keyword>
  <keyword>Advanced Solid Tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

